← Back to Screener
Cybin Inc. Common Stock (HELP)
Price$4.15
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-41.56%
Price vs S&P 500 (4W)-20.27%
VGM Score25.43
Market Capitalization$1.38M
All Metrics
Book Value / Share (Quarterly)$3.95
Cash Flow / Share (Quarterly)$-1.72
Price vs S&P 500 (YTD)-55.33%
EPS (TTM)$-3.56
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-3.56
EPS (Annual)$-11.04
ROI (Annual)-88.81%
Gross Margin (Annual)23.11%
Cash / Share (Quarterly)$2.81
ROA (Last FY)-80.45%
EBITD / Share (TTM)$-3.34
Cash Flow / Share (Annual)$-3.43
P/B Ratio0.01x
P/B Ratio (Quarterly)2.11x
Net Income / Employee (Annual)$-972,124
Net Interest Coverage (TTM)-696.23x
ROA (TTM)-55.95%
EPS Incl Extra (Annual)$-11.04
Current Ratio (Annual)7.75x
Quick Ratio (Quarterly)12.44x
3-Month Avg Trading Volume0.02M
52-Week Price Return-52.23%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.51
P/S Ratio (Annual)2.22x
Asset Turnover (Annual)0.01x
52-Week High$12.70
EPS Excl Extra (Annual)$-11.04
26-Week Price Return-33.64%
Quick Ratio (Annual)6.71x
13-Week Price Return-24.94%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.78x
Enterprise Value$-138.86M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3728.56%
Cash / Share (Annual)$3.12
3-Month Return Std Dev99.64%
Net Income / Employee (TTM)$-1,891,351
ROE (Last FY)-88.81%
Net Interest Coverage (Annual)-5.98x
EPS Basic Excl Extra (Annual)$-11.04
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.56
ROI (TTM)-60.13%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-76.60%
Year-to-Date Return-47.97%
5-Day Price Return-10.39%
EPS Normalized (Annual)$-11.04
Net Profit Margin (Annual)-3728.56%
Month-to-Date Return-7.96%
EBITD / Share (Annual)$-10.39
Operating Margin (Annual)-3625.34%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.56
P/TBV (Quarterly)2.37x
Price vs S&P 500 (13W)-33.19%
Revenue / Share (TTM)$0.00
ROE (TTM)-65.64%
52-Week Low$5.70
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HELPCybin Inc. Common Stock | — | — | D | $4.15 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Helus Pharma is a clinical-stage biopharmaceutical company developing serotonergic agonists to treat mental health disorders, including depression and anxiety. The company's lead candidate, HLP003, is in Phase 3 development for adjunctive treatment of major depressive disorder. With operations across North America and Europe, Helus Pharma addresses an underserved market for innovative neuropsychiatric therapies.